175 related articles for article (PubMed ID: 36960680)
61. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).
Thiede C; Koch S; Creutzig E; Steudel C; Illmer T; Schaich M; Ehninger G
Blood; 2006 May; 107(10):4011-20. PubMed ID: 16455956
[TBL] [Abstract][Full Text] [Related]
62. Gastric Myeloid Sarcoma Mimicking a Scirrhous Gastric Cancer.
Taminishi-Katsuragawa Y; Shimura Y; Inoue Y; Matsumura-Kimoto Y; Tsukamoto T; Mizutani S; Kobayashi T; Takeda-Miyata N; Nishimura A; Takatsuka K; Kuroda J
Intern Med; 2022 Apr; 61(8):1231-1235. PubMed ID: 34615821
[TBL] [Abstract][Full Text] [Related]
63. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.
Schnittger S; Schoch C; Kern W; Mecucci C; Tschulik C; Martelli MF; Haferlach T; Hiddemann W; Falini B
Blood; 2005 Dec; 106(12):3733-9. PubMed ID: 16076867
[TBL] [Abstract][Full Text] [Related]
64. When the good go bad: Mutant NPM1 in acute myeloid leukemia.
Kunchala P; Kuravi S; Jensen R; McGuirk J; Balusu R
Blood Rev; 2018 May; 32(3):167-183. PubMed ID: 29157973
[TBL] [Abstract][Full Text] [Related]
65. Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias.
Rocquain J; Carbuccia N; Trouplin V; Raynaud S; Murati A; Nezri M; Tadrist Z; Olschwang S; Vey N; Birnbaum D; Gelsi-Boyer V; Mozziconacci MJ
BMC Cancer; 2010 Aug; 10():401. PubMed ID: 20678218
[TBL] [Abstract][Full Text] [Related]
66. Cytoplasmic expression of nucleophosmin accurately predicts mutation in the nucleophosmin gene in patients with acute myeloid leukemia and normal karyotype.
Luo J; Qi C; Xu W; Kamel-Reid S; Brandwein J; Chang H
Am J Clin Pathol; 2010 Jan; 133(1):34-40. PubMed ID: 20023256
[TBL] [Abstract][Full Text] [Related]
67. Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia.
Scholl S; Theuer C; Scheble V; Kunert C; Heller A; Mügge LO; Fricke HJ; Höffken K; Wedding U
Eur J Haematol; 2008 Mar; 80(3):208-15. PubMed ID: 18081718
[TBL] [Abstract][Full Text] [Related]
68. Single-center, observational study of AML/MDS-EB with IDH1/2 mutations: genetic profile, immunophenotypes, mutational kinetics and outcomes.
Papadopoulou V; Schoumans J; Basset V; Solly F; Pasquier J; Blum S; Spertini O
Hematology; 2023 Dec; 28(1):2180704. PubMed ID: 36815747
[TBL] [Abstract][Full Text] [Related]
69. [Detection of NPM1, FLT3 and C-KIT mutations in acute myeloid leukemia and their prognostic analysis].
Li L; Lyu XD; Mi RH; Ding J; Chen L; Wang Q; Yin QS; Hu JY; Fan RH; Wei XD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):601-6. PubMed ID: 23815906
[TBL] [Abstract][Full Text] [Related]
70. The correlation of next-generation sequencing-based genotypic profiles with clinicopathologic characteristics in NPM1-mutated acute myeloid leukemia.
Wang B; Yang B; Wu W; Liu X; Li H
BMC Cancer; 2021 Jul; 21(1):788. PubMed ID: 34238278
[TBL] [Abstract][Full Text] [Related]
71. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications.
Falini B; Bolli N; Liso A; Martelli MP; Mannucci R; Pileri S; Nicoletti I
Leukemia; 2009 Oct; 23(10):1731-43. PubMed ID: 19516275
[TBL] [Abstract][Full Text] [Related]
72. Nucleophosmin mutation in de-novo acute myeloid leukemia.
Rastogi P; Naseem S; Varma N; Varma S
Asia Pac J Clin Oncol; 2016 Mar; 12(1):77-85. PubMed ID: 26669619
[TBL] [Abstract][Full Text] [Related]
73. Prognostic impact of NPM1 mutations in Serbian adult patients with acute myeloid leukemia.
Kuzmanovic M; Tosic N; Colovic N; Karan-Djurasevic T; Spasovski V; Radmilovic M; Nikcevic G; Suvajdzic-Vukovic N; Tomin D; Vidovic A; Virijevic M; Pavlovic S; Colovic M
Acta Haematol; 2012; 128(4):203-12. PubMed ID: 22906848
[TBL] [Abstract][Full Text] [Related]
74. Risk stratification using FLT3 and NPM1 in acute myeloid leukemia patients autografted in first complete remission.
Shouval R; Labopin M; Bomze D; Baerlocher GM; Capria S; Blaise D; Hänel M; Forcade E; Huynh A; Saccardi R; Milone G; Zuckerman T; Reményi P; Versluis J; Esteve J; Gorin NC; Mohty M; Nagler A
Bone Marrow Transplant; 2020 Dec; 55(12):2244-2253. PubMed ID: 32388535
[TBL] [Abstract][Full Text] [Related]
75. CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia.
Dang H; Chen Y; Kamel-Reid S; Brandwein J; Chang H
Hum Pathol; 2013 Oct; 44(10):2038-46. PubMed ID: 23701943
[TBL] [Abstract][Full Text] [Related]
76. Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy.
Daver N; Liu Dumlao T; Ravandi F; Pierce S; Borthakur G; Pemmaraju N; Nazha A; Faderl S; Jabbour E; Garcia-Manero G; Cortes J; Kantarjian H; Quintás-Cardama A
Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):435-40. PubMed ID: 23763915
[TBL] [Abstract][Full Text] [Related]
77. NPM1 mutations in therapy-related acute myeloid leukemia with uncharacteristic features.
Andersen MT; Andersen MK; Christiansen DH; Pedersen-Bjergaard J
Leukemia; 2008 May; 22(5):951-5. PubMed ID: 18273044
[TBL] [Abstract][Full Text] [Related]
78. Mutation profile of acute myeloid leukaemia in a Chinese cohort by targeted next-generation sequencing.
Lit BMW; Guo BB; Malherbe JAJ; Kwong YL; Erber WN
Cancer Rep (Hoboken); 2022 Oct; 5(10):e1573. PubMed ID: 34617422
[TBL] [Abstract][Full Text] [Related]
79. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.
Becker H; Marcucci G; Maharry K; Radmacher MD; Mrózek K; Margeson D; Whitman SP; Wu YZ; Schwind S; Paschka P; Powell BL; Carter TH; Kolitz JE; Wetzler M; Carroll AJ; Baer MR; Caligiuri MA; Larson RA; Bloomfield CD
J Clin Oncol; 2010 Feb; 28(4):596-604. PubMed ID: 20026798
[TBL] [Abstract][Full Text] [Related]
80. Allogeneic hematopoietic stem cell transplantation could improve survival of cytogenetically normal adult acute myeloid leukemia patients with DNMT3A mutations.
Xu Y; Sun Y; Shen H; Ding L; Yang Z; Qiu H; Sun A; Chen S; Wu D
Am J Hematol; 2015 Nov; 90(11):992-7. PubMed ID: 26223865
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]